Twist2 amplification in rhabdomyosarcoma represses myogenesis and promotes oncogenesis by redirecting MyoD DNA binding

Stephen Li, Kenian Chen, Yichi Zhang, Spencer D. Barnes, Priscilla Jaichander, Yanbin Zheng, Mohammed Hassan, Venkat S. Malladi, Stephen X Skapek, Lin Xu, Rhonda S Bassel-Duby, Eric N Olson, Ning Liu

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Rhabdomyosarcoma (RMS) is an aggressive pediatric cancer composed of myoblast-like cells. Recently, we discovered a unique muscle progenitor marked by the expression of the Twist2 transcription factor. Genomic analyses of 258 RMS patient tumors uncovered prevalent copy number amplification events and increased expression of TWIST2 in fusion-negative RMS. Knockdown of TWIST2 in RMS cells results in up-regulation of MYOGENIN and a decrease in proliferation, implicating TWIST2 as an oncogene in RMS. Through an inducible Twist2 expression system, we identified Twist2 as a reversible inhibitor of myogenic differentiation with the remarkable ability to promote myotube dedifferentiation in vitro. Integrated analysis of genome-wide ChIP-seq and RNA-seq data revealed the first dynamic chromatin and transcriptional landscape of Twist2 binding during myogenic differentiation. During differentiation, Twist2 competes with MyoD at shared DNA motifs to direct global gene transcription and repression of the myogenic program. Additionally, Twist2 shapes the epigenetic landscape to drive chromatin opening at oncogenic loci and chromatin closing at myogenic loci. These epigenetic changes redirect MyoD binding from myogenic genes toward oncogenic, metabolic, and growth genes. Our study reveals the dynamic interplay between two opposing transcriptional regulators that control the fate of RMS and provides insight into the molecular etiology of this aggressive form of cancer.

Original languageEnglish (US)
Pages (from-to)626-640
Number of pages15
JournalGenes & development
Volume33
Issue number11-12
DOIs
StatePublished - Jun 1 2019

Fingerprint

Rhabdomyosarcoma
Muscle Development
Carcinogenesis
DNA
Chromatin
Epigenomics
Genes
Neoplasms
Nucleotide Motifs
Myoblasts
Skeletal Muscle Fibers
Oncogenes
Transcription Factors
Up-Regulation
Genome
RNA
Pediatrics
Muscles
Growth

Keywords

  • bHLH
  • chromosome amplification
  • dedifferentiation
  • histone modification
  • rhabdomyosarcoma
  • skeletal muscle

ASJC Scopus subject areas

  • Genetics
  • Developmental Biology

Cite this

Twist2 amplification in rhabdomyosarcoma represses myogenesis and promotes oncogenesis by redirecting MyoD DNA binding. / Li, Stephen; Chen, Kenian; Zhang, Yichi; Barnes, Spencer D.; Jaichander, Priscilla; Zheng, Yanbin; Hassan, Mohammed; Malladi, Venkat S.; Skapek, Stephen X; Xu, Lin; Bassel-Duby, Rhonda S; Olson, Eric N; Liu, Ning.

In: Genes & development, Vol. 33, No. 11-12, 01.06.2019, p. 626-640.

Research output: Contribution to journalArticle

Li, Stephen ; Chen, Kenian ; Zhang, Yichi ; Barnes, Spencer D. ; Jaichander, Priscilla ; Zheng, Yanbin ; Hassan, Mohammed ; Malladi, Venkat S. ; Skapek, Stephen X ; Xu, Lin ; Bassel-Duby, Rhonda S ; Olson, Eric N ; Liu, Ning. / Twist2 amplification in rhabdomyosarcoma represses myogenesis and promotes oncogenesis by redirecting MyoD DNA binding. In: Genes & development. 2019 ; Vol. 33, No. 11-12. pp. 626-640.
@article{cac9c99feb6745ff9a453c6f55476c77,
title = "Twist2 amplification in rhabdomyosarcoma represses myogenesis and promotes oncogenesis by redirecting MyoD DNA binding",
abstract = "Rhabdomyosarcoma (RMS) is an aggressive pediatric cancer composed of myoblast-like cells. Recently, we discovered a unique muscle progenitor marked by the expression of the Twist2 transcription factor. Genomic analyses of 258 RMS patient tumors uncovered prevalent copy number amplification events and increased expression of TWIST2 in fusion-negative RMS. Knockdown of TWIST2 in RMS cells results in up-regulation of MYOGENIN and a decrease in proliferation, implicating TWIST2 as an oncogene in RMS. Through an inducible Twist2 expression system, we identified Twist2 as a reversible inhibitor of myogenic differentiation with the remarkable ability to promote myotube dedifferentiation in vitro. Integrated analysis of genome-wide ChIP-seq and RNA-seq data revealed the first dynamic chromatin and transcriptional landscape of Twist2 binding during myogenic differentiation. During differentiation, Twist2 competes with MyoD at shared DNA motifs to direct global gene transcription and repression of the myogenic program. Additionally, Twist2 shapes the epigenetic landscape to drive chromatin opening at oncogenic loci and chromatin closing at myogenic loci. These epigenetic changes redirect MyoD binding from myogenic genes toward oncogenic, metabolic, and growth genes. Our study reveals the dynamic interplay between two opposing transcriptional regulators that control the fate of RMS and provides insight into the molecular etiology of this aggressive form of cancer.",
keywords = "bHLH, chromosome amplification, dedifferentiation, histone modification, rhabdomyosarcoma, skeletal muscle",
author = "Stephen Li and Kenian Chen and Yichi Zhang and Barnes, {Spencer D.} and Priscilla Jaichander and Yanbin Zheng and Mohammed Hassan and Malladi, {Venkat S.} and Skapek, {Stephen X} and Lin Xu and Bassel-Duby, {Rhonda S} and Olson, {Eric N} and Ning Liu",
year = "2019",
month = "6",
day = "1",
doi = "10.1101/gad.324467.119",
language = "English (US)",
volume = "33",
pages = "626--640",
journal = "Genes and Development",
issn = "0890-9369",
publisher = "Cold Spring Harbor Laboratory Press",
number = "11-12",

}

TY - JOUR

T1 - Twist2 amplification in rhabdomyosarcoma represses myogenesis and promotes oncogenesis by redirecting MyoD DNA binding

AU - Li, Stephen

AU - Chen, Kenian

AU - Zhang, Yichi

AU - Barnes, Spencer D.

AU - Jaichander, Priscilla

AU - Zheng, Yanbin

AU - Hassan, Mohammed

AU - Malladi, Venkat S.

AU - Skapek, Stephen X

AU - Xu, Lin

AU - Bassel-Duby, Rhonda S

AU - Olson, Eric N

AU - Liu, Ning

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Rhabdomyosarcoma (RMS) is an aggressive pediatric cancer composed of myoblast-like cells. Recently, we discovered a unique muscle progenitor marked by the expression of the Twist2 transcription factor. Genomic analyses of 258 RMS patient tumors uncovered prevalent copy number amplification events and increased expression of TWIST2 in fusion-negative RMS. Knockdown of TWIST2 in RMS cells results in up-regulation of MYOGENIN and a decrease in proliferation, implicating TWIST2 as an oncogene in RMS. Through an inducible Twist2 expression system, we identified Twist2 as a reversible inhibitor of myogenic differentiation with the remarkable ability to promote myotube dedifferentiation in vitro. Integrated analysis of genome-wide ChIP-seq and RNA-seq data revealed the first dynamic chromatin and transcriptional landscape of Twist2 binding during myogenic differentiation. During differentiation, Twist2 competes with MyoD at shared DNA motifs to direct global gene transcription and repression of the myogenic program. Additionally, Twist2 shapes the epigenetic landscape to drive chromatin opening at oncogenic loci and chromatin closing at myogenic loci. These epigenetic changes redirect MyoD binding from myogenic genes toward oncogenic, metabolic, and growth genes. Our study reveals the dynamic interplay between two opposing transcriptional regulators that control the fate of RMS and provides insight into the molecular etiology of this aggressive form of cancer.

AB - Rhabdomyosarcoma (RMS) is an aggressive pediatric cancer composed of myoblast-like cells. Recently, we discovered a unique muscle progenitor marked by the expression of the Twist2 transcription factor. Genomic analyses of 258 RMS patient tumors uncovered prevalent copy number amplification events and increased expression of TWIST2 in fusion-negative RMS. Knockdown of TWIST2 in RMS cells results in up-regulation of MYOGENIN and a decrease in proliferation, implicating TWIST2 as an oncogene in RMS. Through an inducible Twist2 expression system, we identified Twist2 as a reversible inhibitor of myogenic differentiation with the remarkable ability to promote myotube dedifferentiation in vitro. Integrated analysis of genome-wide ChIP-seq and RNA-seq data revealed the first dynamic chromatin and transcriptional landscape of Twist2 binding during myogenic differentiation. During differentiation, Twist2 competes with MyoD at shared DNA motifs to direct global gene transcription and repression of the myogenic program. Additionally, Twist2 shapes the epigenetic landscape to drive chromatin opening at oncogenic loci and chromatin closing at myogenic loci. These epigenetic changes redirect MyoD binding from myogenic genes toward oncogenic, metabolic, and growth genes. Our study reveals the dynamic interplay between two opposing transcriptional regulators that control the fate of RMS and provides insight into the molecular etiology of this aggressive form of cancer.

KW - bHLH

KW - chromosome amplification

KW - dedifferentiation

KW - histone modification

KW - rhabdomyosarcoma

KW - skeletal muscle

UR - http://www.scopus.com/inward/record.url?scp=85067216003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067216003&partnerID=8YFLogxK

U2 - 10.1101/gad.324467.119

DO - 10.1101/gad.324467.119

M3 - Article

VL - 33

SP - 626

EP - 640

JO - Genes and Development

JF - Genes and Development

SN - 0890-9369

IS - 11-12

ER -